Compared to the «basic group,» the «augmented group» who received the stimulant drug and parent training plus
risperidone showed significant improvement (on average with moderately better behavior) on the Nisonger Child Behavior Rating Form (NCBRF) Disruptive - Total Scale, the NCBRF Social Competence subscale and the Reactive Aggression part of the Antisocial Behavior Scale.
Not exact matches
After controlling for other possible contributing mental and physical conditions and their associated behaviors, researchers found no significant increased risk for either congenital malformations or cardiac malformations among women who took either typical or atypical APMs in the first 90 days of pregnancy, with the possible exception of
risperidone which continued to
show a slightly increased risk.
Now, L. Eugene Arnold and Michael Aman, professors emeritus at the Nisonger Center at Ohio State's Wexner Medical Center, and their colleagues have published a study, available online in the Journal of Child and Adolescent Psychopharmacology (JCAP),
showing the addition of
risperidone to parent training and a stimulant also improves teachers» assessments of anxiety and social avoidance.
An open - label trial using low doses (mean 1.2 ± 0.5 mg) of
risperidone in children and adolescents with SMD
showed significant reductions in irritability scores.17
No medications are FDA - approved for the treatment of ODD in the U.S. Nonetheless, clinical experience has
shown that the majority of children and adolescents with ODD do
show signs of improvement with a low dose of atypical neuroleptics — arippirazole (Abilify) and
risperidone (Risperidal), for example.